-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Wedbush Downgrades Fate Therapeutics to Neutral, Announces $7 Price Target

Benzinga · 01/06/2023 07:07
Wedbush analyst David Nierengarten downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Neutral and announces $7 price target.